XML 87 R28.htm IDEA: XBRL DOCUMENT

Note 20 - Settlement Expense	12 Months Ended
Note 20 - Settlement Expense	Dec. 31, 2019
Notes to Financial Statements
Settlement Expense [Text Block]	20. Settlement expense On September 30, 2019, the Company entered into a Settlement Agreement and Release with Oxford University Innovation Limited, or OUI, or the OUI Settlement Agreement, to resolve outstanding disputes arising from a license agreement with OUI. The terms of the OUI Settlement Agreement are confidential. On June 18, 2018, the Company entered into a Settlement Agreement with the former shareholders of Immunetics, Inc., or the Immunetics Settlement Agreement, to resolve disputes arising from the Agreement and Plan of Merger dated October 12, 2016. The terms of the Immunetics Settlement Agreement are confidential. The Company has no further obligations under the Immunetics Settlement Agreement. On June 30, 2017, the Company and Statens Serum Institut, or SSI, entered into a Release and Settlement Agreement, or the SSI Settlement Agreement, to resolve outstanding disputes arising from the license agreement with SSI. The terms of the SSI Settlement Agreement are confidential.